Use of the aerosol rabbitpox virus model for evaluation of anti-poxvirus agents

Viruses

Volumn 2, Issue 9, 2010, Pages 2096-2107

  Roy, Chad J ^a,b   Voss, Thomas G ^b  

^a TULANE NATIONAL PRIMATE RESEARCH CENTER   (United States)

^b TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Aerobiology; Aerosol; Animal model; Rabbitpox

Indexed keywords

CIDOFOVIR; HYPERIMMUNE GLOBULIN; SMALLPOX VACCINE; TECOVIRIMAT; THIOSEMICARBAZONE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AEROSOL; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; CYTOMEGALOVIRUS RETINITIS; DISEASE MODEL; DRUG SCREENING; EXPERIMENTAL INFECTION; HUMAN; LOW DRUG DOSE; NONHUMAN; PARTICLE SIZE; POXVIRUS; POXVIRUS INFECTION; RABBIT; RESPIRATORY TRACT INFECTION; REVIEW; SMALLPOX; VIRUS PATHOGENESIS; VIRUS REPLICATION; VIRUS TRANSMISSION;

ANIMALIA; ORYCTOLAGUS CUNICULUS; POXVIRIDAE; RABBITPOX VIRUS; RODENTIA; VARIOLA; VARIOLA VIRUS;

EID: 79952147365     PISSN: None     EISSN: 19994915     Source Type: Journal    
DOI: 10.3390/v2092096     Document Type: Review

References (38)

1. Wallin, A.; Luksiene, Z.; Zagminas, K.; Surkiene, G. Public health and bioterrorism: Renewed threat of anthrax and smallpox. Medicina (Kaunas) 2007, 43, 278-284.
2. Jansen, J. Experimenteel onderzoek van Kon-ijnensterfte door een filteebaar virus. Tijdschr. Diergeneesk. 1942, 69, 505-514.
3. Greene, H.S.N. A pandemic of rabbit-pox. Proc. Soc. Exp. Biol. Med. 1933, 30, 892-894.
4. Greene, D.R. Rabbit pox II. Pathology of the epidemic disease. J. Exp. Med. 1934, 60, 441-455.
5. Li, G.; Chen, N.; Roper, R.L.; Feng Z.; Hunter, A.; Danila, M.; Lefkowitz, E.J.; Buller, R.M.; Upton, C. Complete coding sequences of the rabbitpox virus genome. J. Gen. Virol. 2005, 86, 2969-2977.
6. Rondle, C.J.; Dumbell, K.R. A poxvirus antigen associated with pathogenicity for rabbits. J. Hyg. 1982, 89, 383-388.
7. Boulter, E.A. Value of serotherapy in a virus disease (rabbit pox). Lancet 1961, 2, 1012-1015.
8. Boulter, E.A. Protection against poxviruses. Proc. R. Soc. Med. 1969, 62, 295-297.
9. Westwood, J.C.; Boulter, E.A.; Bowen, E.T.; Maber, H.B. Experimental respiratory infection with poxviruses. I. Clinical virological and epidemiological studies. Brit. J. Exp. Pathol. 1966, 47, 453-465.
10. Lancaster, M.C.; Boulter, E.A.; Westwood, J.C.; Randles, J. Experimental respiratory infection with poxviruses. II. Pathological studies. Brit. J. Exp. Pathol. 1966, 47, 466-471.
11. Bedson, H.S.; Duckworth, M.J. Rabbit pox: An experimental study of the pathways of infection in rabbits. J. Pathol. Bacteriol. 1963, 85, 1-20.
12. Ali, A.N.; Turner, P.C.; Brooks, M.A.; Moyer, R.W. The SPI-1 gene of rabbitpox virus determines host range and is required for hemorrhagic pock formation. Virology 1994, 202, 305-314.
13. Moyer, R.W.; Rothe, C.T. The white pock mutants of rabbit poxvirus. I. Spontaneous host range mutants contain deletions. Virology 1980, 102, 119-132.
14. Adams, M.M.; Rice, A.D.; Moyer, R.W. Rabbitpox virus and vaccinia virus infection of rabbits as a model for human smallpox. J. Virol. 2007, 81, 11084-11095.
15. Brown, C.K.; Bloom, D.C.; Moyer, R.W. The nature of naturally occurring mutations in the hemagglutinin gene of vaccinia virus and the sequence of immediately adjacent genes. Virus Genes 1991, 5, 235-242.
16. Roy, C.J. Rabbitpox: An Aerosol Model for the Study of Aerosolized Poxviruses. J. Antivir. Res. 2004, 43, S34.
17. Nalca, A.; Hatkin, J.M.; Garza, N.L.; Nichols, D.K.; Norris, S.W.; Hruby, D.E.; Jordan, R. Evaluation of orally delivered ST-246 as postexposure prophylactic and antiviral therapeutic in an aerosolized rabbitpox rabbit model. Antivir. Res. 2008, 79, 121-127.
18. Garza, N.L.; Hatkin, J.M.; Livingston, V.; Nichols, D.K.; Chaplin, P.J.; Volkmann, A.; Fisher, D.; Nalca, A. Evaluation of the efficacy of modified vaccinia Ankara (MVA)/IMVAMUNE against aerosolized rabbitpox virus in a rabbit model. Vaccine 2009, 27, 5496-5504.
19. Roy, C.J. Tulane University, New Orleans, LA, USA. Unpublished work, 2010.
20. Thomas, G. Sampling rabbit pox aerosols of natural origin. J. Hyg. (Lond.) 1970, 68, 511-517.
21. Dahlback, M.; Wollmer, P.; Jonson, B. Selective deposition of inhaled aerosols to mechanically ventilated rabbits. J. Aerosol. Med. 1994, 7, 315-324.
22. Roy, C.J.; Nichols, D.K. Pathology of aerosolized rabbitpox virus infection in rabbits. Vet. Pathol. 2006, 43, 831.
23. De Clercq, E.; Neyts, J. Therapeutic potential of nucleoside/nucleotide analogues against poxvirus infections. Rev. Med. Virol. 2004, 14, 289-300.
24. De Clercq, E. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections. Clin. Microbiol. Rev. 2001, 14, 382-397.
25. De Clercq, E. Cidofovir in the treatment of poxvirus infections. Antivir. Res. 2002, 55, 1-13.
26. Neyts, J.; De Clercq, E. Therapy and short-term prophylaxis of poxvirus infections: Historical background and perspectives. Antivir. Res. 2003, 57, 25-33.
27. Smee, D.F.; Sidwell, R.W. A review of compounds exhibiting anti-orthopoxvirus activity in animal models. Antivir. Res. 2003, 57, 41-52.
28. Boyle, D.B. Quantitative assessment of poxvirus promoters in fowlpox and vaccinia virus recombinants. Virus Genes 1992, 6, 281-290.
29. Kern, E.R. In vitro activity of potential anti-poxvirus agents. Antivir. Res. 2003, 57, 35-40.
30. Hartings, J.M.; Roy, C.J. The automated bioaerosol exposure system: preclinical platform development and a respiratory dosimetry application with nonhuman primates. J. Pharmacol. Toxicol. Method. 2004, 49, 39-55.
31. Roy, C.J.; Pitt, L.M.L. Infectious disease aerobiology: Aerosol challenge methods. In Biodefense: Research Methodology and Animal Models; Swearengen, J.L., Ed.; CRC Press: Boca Raton, FL, USA, 2005; Chapter 5, pp. 61-76.
32. Rao, A.R.; McFadzean, J.A.; Squires, S. The laboratory and clinical assessment of an isothiazole thiosemicarbazone (M 2 b 7714) against pox viruses. Ann. N. Y. Acad. Sci. 1965, 130, 118-127.
33. Quenelle, D.C.; Keith, K.A.; Kern, E.R. In vitro and in vivo evaluation of isatin-beta-thiosemicarbazone and marboran against vaccinia and cowpox virus infections. Antivir. Res. 2006, 71, 24-30.
34. De Clercq, E. Cidofovir in the therapy and short-term prophylaxis of poxvirus infections. Trends Pharmacol. Sci. 2002, 23, 456-458.
35. Bray, M.; Roy, C.J. Antiviral prophylaxis of smallpox. J. Antimicrob. Chemother. 2004, 54, 1-5.
36. Yang, G.; Pevear, D.C.; Davies, M.H.; Collett, M.S.; Bailey, T.; Rippen, S.; Barone, L.; Burns, C.; Rhodes, G.; Tohan, S.; Huggins, J.W.; Baker, R.O.; Buller, R.L.M.; Touchette, E.; Waller, K.; Schriewer, J.; Neyts, J.; DeClercq, E.; Jones, K.; Hruby, D.; Jordan, R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus Challenge. J. Virol. 2005, 79, 13139-13149.
37. Jordan, R.; Goff, A.; Frimm, A.; Corrado, M.L.; Hensley, L.E.; Byrd, C.M.; Mucker, E.; Shamblin, J.; Bolken, T.C.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Twenhafel, N.; Tyavanagimatt, S.; Amantana, A.; Chinsangaram, J.; Hruby, D.E.; Huggins, J. ST-246 antiviral efficacy in a nonhuman primate monkeypox model: Determination of the minimal effective dose and human dose justification. Antimicrob. Agents Chemother. 2009, 53, 1817-1822.
38. Huggins, J.; Goff, A.; Hensley, L.; Mucker, E.; Shamblin, J.; Wlazlowski, C.; Johnson, W.; Chapman, J.; Larsen, T.; Twenhafel, N.; Karem, K.; Damon, I.K.; Byrd, C.M.; Bolken, T.C.; Jordan, R.; Hruby, D. Nonhuman primates are protected from smallpox virus or monkeypox virus challenges by the antiviral drug ST-246. Antimicrob. Agents Chemother. 2009, 53, 2620-2625.